Semaphorin 4D expression is associated with a poor clinical outcome in cervical cancer patients

Microvascular Research

Volumn 93, Issue , 2014, Pages 1-8

  Liu, Huidong ^a   Yang, Yanmei ^a   Xiao, Jianbing ^a   Yang, Shucai ^a   Liu, Yan ^b   Kang, Wenhui ^a   Li, Xinlei ^a   Zhang, Fengmin ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b Mudanjiang First Hospital   (China)

Author keywords

Cervical cancer; Invasiveness; Lymphangiogenesis; Outcome; Semaphorin 4D; VEGF C; VEGF D

Indexed keywords

GUANOSINE TRIPHOSPHATASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SEMAPHORIN; SEMAPHORIN 4D; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; VASCULOTROPIN C; VASCULOTROPIN D; CD100 ANTIGEN; CELL SURFACE RECEPTOR; LEUKOCYTE ANTIGEN; NERVE PROTEIN; PLXNB1 PROTEIN, HUMAN; RHOA PROTEIN, HUMAN; TUMOR MARKER; VEGFC PROTEIN, HUMAN; VEGFD PROTEIN, HUMAN;

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CAPILLARY DENSITY; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENZYME ACTIVATION; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; METASTASIS POTENTIAL; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; UTERINE CERVIX CANCER; WESTERN BLOTTING; ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; ADULT; CELL MOTION; COMPARATIVE STUDY; FEMALE; GENETIC TRANSFECTION; GENETICS; HELA CELL LINE; KAPLAN MEIER METHOD; LYMPH VESSEL; LYMPHANGIOGENESIS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RNA INTERFERENCE; SECONDARY; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TIME; TUMOR INVASION; UTERINE CERVIX TUMOR;

ADENOCARCINOMA; ADULT; ANTIGENS, CD; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; CELL MOVEMENT; FEMALE; HELA CELLS; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; LYMPHATIC VESSELS; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM INVASIVENESS; NERVE TISSUE PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, CELL SURFACE; RHOA GTP-BINDING PROTEIN; RNA INTERFERENCE; SEMAPHORINS; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; UTERINE CERVICAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR D;

EID: 84901235012     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2014.02.007     Document Type: Article

References (36)

1. Alitalo K., Tammela T., Petrova T.V. Lymphangiogenesis in development and human disease. Nature 2005, 438:946-953.
2. Bando H., Weich H.A., Horiguchi S., Funata N., Ogawa T., Toi M. The association between vascular endothelial growth factor-C, its corresponding receptor, VEGFR-3, and prognosis in primary breast cancer: a study with 193 cases. Oncol. Rep. 2006, 15:653-659.
3. Basile J.R., Barac A., Zhu T., Guan K.L., Gutkind J.S. Class IV semaphorins promote angiogenesis by stimulating Rho-initiated pathways through plexin-B. Cancer Res. 2004, 64:5212-5224.
4. Basile J.R., Castilho R.M., Williams V.P., Gutkind J.S. Semaphorin 4D provides a link between axon guidance processes and tumor-induced angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:9017-9022.
5. Basile J.R., Gavard J., Gutkind J.S. Plexin-B1 utilizes RhoA and Rho kinase to promote the integrin-dependent activation of Akt and ERK and endothelial cell motility. J. Biol. Chem. 2007, 282:34888-34895.
6. Christiansen A., Detmar M. Lymphangiogenesis and cancer. Genes Cancer 2011, 2(12):1146-1158.
7. Conrotto P., Valdembri D., Corso S., Serini G., Tamagnone L., Comoglio P.M., Bussolino F., Giordano S. Sema4D induces angiogenesis through Met recruitment by Plexin B1. Blood 2005, 105:4321-4329.
8. Dadras S.S., Lange-Asschenfeldt B., Velasco P., Nguyen L., Vora A., Muzikansky A., Jahnke K., Hauschild A., Hirakawa S., Mihm M.C., Detmar M. Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Mod. Pathol. 2005, 18:1232-1242.
9. Duong T., Koopman P., Francois M. Tumor lymphangiogenesis as a potential therapeutic target. J. Oncol. 2012, 2012:204946.
10. Fiedler U., Christian S., Koidl S., Kerjaschki D., Emmett M.S., Bates D.O., Christofori G., Augustin H.G. The sialomucin CD34 is a marker of lymphatic endothelial cells in human tumors. Am. J. Pathol. 2006, 168(3):1045-1053.
11. Garmy-Susini B., Avraamides C.J., Schmid M.C., Foubert P., Ellies L.G., Barnes L., Feral C., Papayannopoulou T., Lowy A., Blair S.L., Cheresh D., Ginsberg M., Varner J.A. Integrin alpha4beta1 signaling is required for lymphangiogenesis and tumor metastasis. Cancer Res. 2010, 70(8):3042-3051.
12. Gobos Z., Xu X., Chu C.S., Zhang P.J., Acs G. Peritumoral lymphatic density and vascular endothelial growth factor C expression in early-stage squamous cell carcinoma of the uterine cervix. Clin. Cancer Res. 2005, 11(23):18364-18371.
13. Gu C., Giraudo E. The role of semaphorins and their receptors in vascular development and cancer. Exp. Cell Res. 2013, 319(9):1306-1316.
14. Holmqvist A., Gao J., Adell G., Carstensen J., Sun X.F. The location of lymphangiogenesis is an independent prognostic factor in rectal cancers with or without preoperative radiotherapy. Ann. Oncol. 2010, 21:512-517.
15. Jennbacken K., Vallbo C., Wang W., Damber J.E. Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis. Prostate 2005, 65:110-116.
16. Kato S., Kubota K., Shimamura T., Shinohara Y., Kobayashi N., Watanabe S., Yoneda M., Inamori M., Nakamura F., Ishiguro H., Nakaigawa N., Nagashima Y., Taguri M., Kubota Y., Goshima Y., Morita S., Endo I., Maeda S., Nakajima A., Nakagama H. Semaphorin 4D, a lymphocyte semaphorin, enhances tumor cell motility through binding its receptor, plexinB1, in pancreatic cancer. Cancer Sci. 2011, 102(11):2029-2037.
17. Krajewska M., Krajewski S., Epstein J.I., Shabaik A., Sauvageot J., Song K., Kitada S., Reed J.C. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am. J. Pathol. 1996, 148:1567-1576.
18. Langheinrich M.C., Schellerer V., Perrakis A., Lohmüller C., Schildberg C., Naschberger E., Stürzl M., Hohenberger W., Croner R.S. Molecular mechanisms of lymphatic metastasis in solid tumors of the gastrointestinal tract. Int. J. Clin. Exp. Pathol. 2012, 5(7):614-623.
19. Lohela M., Bry M., Tammela T., Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr. Opin. Cell Biol. 2009, 21:154.
20. Mäkinen T., Alitalo K. Lymphangiogenesis in development and disease. Novartis Found. Symp. 2007, 283:87-98.
21. Mäkinen T., Norrmén C., Petrova T.V. Molecular mechanisms of lymphatic vascular development. Cell. Mol. Life Sci. 2007, 64(15):1915-1929.
22. Nathanson S.D. Insights into the mechanisms of lymph node metastasis. Cancer 2003, 98:413-423.
23. Quinn M.A., Benedet J.L., Odicino F., Maisonneuve P., Beller U., Creasman W.T., Heintz A.P., Ngan H.Y., Pecorelli S. Carcinoma of the cervix uteri. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int. J. Gynaecol. Obstet. 2006, 95(Suppl. 1):S43-S103.
24. Ran S., Volk L., Hall K., Flister M.J. Lymphangiogenesis and lymphatic metastasis in breast cancer. Pathophysiology 2010, 17(4):229-251.
25. Schacht V., Dadras S.S., Johnson L.A., Jackson D.G., Hong Y.K., Detmar M. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am. J. Pathol. 2005, 166:913-921.
26. Siegfried G., Basak A., Cromlish J.A., Benjannet S., Marcinkiewicz J., Chrétien M., Seidah N.G., Khatib A.M. The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis. J. Clin. Invest. 2003, 111:1723-1732.
27. Sierra J.R., Corso S., Caione L., Cepero V., Conrotto P., Cignetti A., Piacibello W., Kumanogoh A., Kikutani H., Comoglio P.M., Tamagnone L., Giordano S. Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages. J. Exp. Med. 2008, 205(7):1673-1685.
28. Sleeman J.P., Thiele W. Tumor metastasis and the lymphatic vasculature. Int. J. Cancer 2009, 125(12):2747-2756.
29. Soong J., Chen Y., Shustef E.M., Scott G.A. Sema4D, the ligand for Plexin B1, suppresses c-Met activation and migration and promotes melanocyte survival and growth. J. Invest. Dermatol. 2012, 132(4):1230-1238.
30. Su J.L., Yen C.J., Chen P.S., Chuang S.E., Hong C.C., Kuo I.H., Chen H.Y., Hung M.C., Kuo M.L. The role of the VEGF-C/VEGFR-3 axis in cancer progression. Br. J. Cancer 2007, 96:541-545.
31. Tobler N.E., Detmar M. Tumor and lymph node lymphangio-genesis-impact on cancer metastasis. J. Leukoc. Biol. 2006, 80:691-696.
32. Toyoki H., Fujimoto J., Sato E., Sakaguchi H., Tamaya T. Clinical implications of expression of cyclooxygenase-2 related to angiogenesis in uterine endometrial cancers. Ann. Oncol. 2005, 16(1):51-55.
33. Tran T.S., Kolodkin A.L., Bharadwaj R. Semaphorin regulation of cellular morphology. Annu. Rev. Cell Dev. Biol. 2007, 23:263-292.
34. Zhou H., Binmadi N.O., Yang Y.H., Proia P., Basile J.R. Semaphorin 4D cooperates with VEGF to promote angiogenesis and tumor progression. Angiogenesis 2012, 15(3):391-407.
35. Zhou H., Yang Y.H., Binmadi N.O., Proia P., Basile J.R. The hypoxia-inducible factor-responsive proteins semaphorin 4D and vascular endothelial growth factor promote tumor growth and angiogenesis in oral squamous cell carcinoma. Exp. Cell Res. 2012, 318(14):1685-1698.
36. Zwaans B.M., Bielenberg D.R. Potential therapeutic strategies for lymphatic metastasis. Microvasc. Res. 2007, 74(2-3):145-158.